Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 7/20 | 0.60 |
| ▸ | CNR2 | P34972 | 6/20 | 0.60 |
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30497875 | 0.96 | CNR1 (0.61) | CNR1CNR2TSHRCYP1A2CYP3A4 | |
| SCHEMBL6948768 | 0.96 | CNR1 (0.61) | CNR1CNR2TSHRCYP1A2CYP3A4 | |
| SCHEMBL3017718 | 0.91 | TSHR (0.53) | CNR1CNR2TSHRCYP1A2CYP3A4 | |
| SCHEMBL15897843 | 0.90 | PKM (0.52) | CNR1CNR2TSHRCYP1A2CYP3A4 | |
| SCHEMBL6944701 | 0.87 | CNR1 (0.59) | CNR1CNR2TSHRHSD17B10KDM4E | |
| SCHEMBL8877416 | 0.87 | CNR1 (0.65) | CNR1CNR2TSHRHSD17B10KDM4E | |
| SCHEMBL15897842 | 0.87 | PKM (0.55) | CNR1CNR2TSHRCYP1A2CYP3A4 | |
| SCHEMBL15897852 | 0.87 | TSHR (0.52) | CNR1CNR2TSHRCYP1A2CYP3A4 | |
| SCHEMBL9342889 | 0.86 | CNR2 (0.58) | CNR1CNR2TSHRHSD17B10KDM4E | |
| SCHEMBL15882017 | 0.85 | CNR1 (0.50) | CNR1CNR2TSHRCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7351704-B2 | Indazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2008-04-01 | — | — | US | claimed |
| CN-1922175-A | As 5-HT4Indazole-carboxamide compounds as receptor agonists | THERAVANCE INC (US) | 2007-02-28 | — | — | CN | claimed |
| EP-1718643-A1 | INDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | Theravance, Inc. (US) | 2006-11-08 | — | — | EP | claimed |
| US-20050197335-A1 | 1-isopropyl-1H-indazole-3-carboxylic acid {(1S,3R,5R)-8-[2-(4-acetylpiperazin-1-yl)-ethyl]8-azabicyclo[3.2.1]oct-3-yl}amide; improved pharmacokinetic, bioavailability; gastrointestinal disorders: irritable bowel syndrome (IBS), chronic constipation, dyspepsia; CNS behavioral, mood disorder | THERAVANCE BIOPHARMA R&D IP, LLC | 2005-09-08 | — | — | US | claimed |
| WO-2005080389-A1 | INDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2005-09-01 | — | — | WO | claimed |
| US-20100261716-A1 | INDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100249123-A1 | NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE | ADDEX PHARMA SA (CH) | 2010-09-30 | — | — | US | disclosed |
| US-7674908-B2 | Indazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2010-03-09 | — | — | US | disclosed |
| US-20080146807-A1 | Indazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-06-19 | — | — | US | disclosed |
| US-7351704-B2 | Indazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2008-04-01 | — | — | US | disclosed |
| CN-1922175-A | As 5-HT4Indazole-carboxamide compounds as receptor agonists | THERAVANCE INC (US) | 2007-02-28 | — | — | CN | disclosed |
| EP-1718643-A1 | INDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | Theravance, Inc. (US) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005080389-A1 | INDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| EP-0829474-B1 | INDAZOLE DERIVATIVES HAVING MONOCYCLIC AMINO GROUP | NISSHIN SEIFUN GROUP INC (JP) | 2003-04-09 | — | — | EP | disclosed |
| US-6096746-A | Indazole compound containing a monocyclic amine structure | NISSHIN FLOUR MILLING CO., LTD. (JP) | 2000-08-01 | — | — | US | disclosed |
| US-5945434-A | TREATMENT OF GASTROINTESTINAL DISORDERS | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1999-08-31 | — | — | US | disclosed |
| EP-0708105-B1 | 5-HT4 receptor agonists | NISSHIN FLOUR MILLING CO (JP) | 1998-12-23 | — | — | EP | disclosed |
| EP-0829474-A1 | INDAZOLE DERIVATIVES HAVING MONOCYCLIC AMINO GROUP | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1998-03-18 | — | — | EP | disclosed |
| US-5684003-A | GASTROINTESTINAL DISORDERS OR ANTIULCER AGENTS | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1997-11-04 | — | — | US | disclosed |
| EP-0708105-A1 | 5-HT4 receptor agonists | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1996-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197335-A1 | 1-isopropyl-1H-indazole-3-carboxylic acid {(1S,3R,5R)-8-[2-(4-acetylpiperazin-1-yl)-ethyl]8-azabicyclo[3.2.1]oct-3-yl}amide; improved pharmacokinetic, bioavailability; gastrointestinal disorders: irritable bowel syndrome (IBS), chronic constipation, dyspepsia; CNS behavioral, mood disorder | HTR4, HTR5A, HTR3C | CNR1 26/4885CNR2 40/4885TSHR 345/4885 |
| US-20080146807-A1 | Indazole-carboxamide compounds as 5-HT4 receptor agonists | HTR4, HTR5A, HTR3B | CNR1 53/4885CNR2 43/4885TSHR 308/4885 |
| US-20100249123-A1 | NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE | FSHR, GNRHR, SHBG | CNR1 90/4885CNR2 198/4885TSHR 19/4885 |
| US-20100261716-A1 | INDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR5A, HTR3B | CNR1 53/4885CNR2 43/4885TSHR 308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.